CRDF - Why Cardiff Oncology Ran Up 1350% in 2020
Cardiff Oncology (NASDAQ: CRDF) is an oncology specialist that had a fantastic year in 2020. The market is excited about the biotech's lead molecule, onvansertib, because it might work to defeat cancer caused by the KRAS mutation, a significant market opportunity. Healthcare bureau chief Corinne Cardina and Motley Fool contributor Taylor Carmichael discuss whether Cardiff is a buy for investors. This Fool Live episode was recorded on Jan. 15, 2021.
Corinne Cardina: Cardiff Oncology. In 2017, it licensed its lead candidate from a private company for just two million dollars after that candidate flopped a phase 1 study. In September, it reported better than expected interim results for advanced stage colon cancer patients. Those patients had a particular mutation called KRAS, meaning it's more aggressive than usual. Investors are looking at this experimental drug as a potential blockbuster. Stock was up 1,350% in 2020. The market cap is still only $625 million. Taylor, what is your green flag and then your red flag for Cardiff Oncology?
For further details see:
Why Cardiff Oncology Ran Up 1,350% in 2020